Journal of Chemistry

Journal of Chemistry / 2019 / Article

Research Article | Open Access

Volume 2019 |Article ID 3410953 | 10 pages | https://doi.org/10.1155/2019/3410953

Identification of Bioactive Compounds and Analysis of Inhibitory Potential of the Digestive Enzymes from Syzygium sp. Extracts

Academic Editor: Teodorico C. Ramalho
Received24 Aug 2018
Revised14 Nov 2018
Accepted03 Dec 2018
Published03 Feb 2019

Abstract

Diabetes and obesity represent major public health problems worldwide. High cost of medicines and drug treatments propose the research for less expensive alternatives, such as enzymatic inhibitors present in medicinal plants from natural sources. An example of such medicinal plant is the jambolan Syzygium sp., which is referred to be hypoglycemic and efficient in weight loss. With this in mind, we identified the bioactive compounds from Syzygium sp. commercial teas and evaluated the inhibitory potential and the antioxidant activity of digestive enzymes from a simulated gastric fluid. Syzygium sp. samples showed low percentages of enzymatic inhibition at 1 : 200 dilution. Antioxidant activity was significant, although it was not expressive of the contents of total phenolic compounds, tannins, flavonoids, flavones, and alkaloids. Maldi-Tof spectroscopy suggested the presence of luteolin in Syzygium sp. samples. Molecular docking predicted that luteolin binds at the α-amylase catalytic site in a similar manner as acarbose, the carbohydrate inhibitor from the enzyme crystallographic structure. The phytochemical content and biological activity were distinct among samples from commercial teas. Thus, additional studies should be conducted to elucidate efficacy and safety of Syzygium sp. extracts, especially in vivo experiments. Syzygium sp. might be in the near future recommended as a medicinal plant in low cost diabetes and obesity treatments.

1. Introduction

Diabetes mellitus and obesity represent some of the greatest public health problems today. Around 90% of individuals who develop type 2 diabetes are obese, and most of these patients have high blood pressure and/or dyslipidemia, in addition to being overweight. Type 2 diabetes is a metabolic disorder that has insulin resistance as its main factor. Type 2 diabetes is the most common type of diabetes, accounting for around 90% of all cases of diabetes. In type 2 diabetes, hyperglycemia is the result of an inadequate production of insulin and inability of the body to respond fully to insulin, defined as insulin resistance. The obese individual has increased adipose tissue producing a number of substances that decrease the body’s ability to convert glucose into energy. Type 2 diabetes already affects children and adolescents [14].

Medicinal plants are rich sources for the development of new pharmaceutical products, such as diabetes and obesity, due to the high presence of secondary metabolites [46]. An example of a medicinal plant is Syzygium sp., which is referenced as a potential hypoglycemic and slimming agent [7, 8]. Known in Brazil as “jambolão,” Syzygium sp. is a tree belonging to the Myrtaceae family. Chanudom and Tangpong [9] worked with aqueous extracts of Syzygium cumini seeds and identified betulinic acid and luteolin as the main inhibitors of pancreatic α-amylase enzyme.

The growing search for safe and effective treatment methods to combat diabetes and obesity has pointed to the use of medicinal plants as a valuable source of inhibitors of digestive enzymes, which inhibit the breakdown of complex carbohydrates and fats in the intestine. These inhibitors exert their antidiabetic effect by hindering the activity of starch hydrolysis, such as α-amylase and α-glucosidase (enzymes present on the small intestinal brush border). α-amylase catalyzes the initial hydrolysis of starch into shorter oligosaccharides and disaccharides by cleavage of glycosidic linkages between the glucose residues. α-amylase inhibitors can effectively delay the digestion of the starch, i.e., delay the formation and absorption of glucose by inhibiting the glycolytic enzymes. This may reduce the rate of glucose uptake into the bloodstream and, thus, alleviate the postprandial increase in plasma glucose in diabetic patients possibly inducing weight loss [1012]. In addition, trypsin inhibitors present in plant extracts may lead to a decrease in protein digestibility, which may also lead to a reduction in weight [13], although it is nutritionally undesirable.

There is a lack of information on the profile of inhibition of the digestive enzymes contained in Syzygium sp. extracts, considering its possible potential to be used in therapy. Also, there is a need for further studies related to its efficacy and mechanism of hypoglycemic and antioxidant action. In order to do that, the procedures performed in this study were to obtain samples of Syzygium sp. commercial teas and prepare crude extracts by using a 1 : 200 infusion method simulating the domestic use; perform enzymatic inhibition trials before and after exposure to gastric fluid; determine the presence of total phenolics, alkaloids, tannins, flavonols, and flavones; evaluate antioxidant capacity; evaluate enzymatic kinetics against inhibitors; investigate the presence of α-amylase inhibitors and perform theoretical studies to elucidate the mode of interaction of amylase by the recognized inhibitors; and investigate the presence of trypsin inhibitors that are nutritionally undesirable. Therefore, using the extracts of Syzygium sp., the objectives of the study were to (a) investigate the presence of bioactive compounds inhibiting digestive enzymes alpha-amylase and trypsin, (b) elucidate the mode of interaction between alpha-amylase and the potential inhibitor luteolin, and (c) clarify the mechanism of the proposed hypoglycemic action of Syzygium sp.

2. Materials and Methods

The analyses were conducted in the Laboratory of Biochemistry (Institute of Biological and Natural Sciences (ICBN)), Laboratory of Theoretical Biophysics (Institute of Exact, Natural and Education Sciences (ICENE)), and Laboratory of Food Engineering (Institute of Technological and Exact Sciences (ICTE))—all at the Federal University of Triângulo Mineiro (UFTM), Brazil.

2.1. Syzygium sp.

Five samples (A, B, C, D, and E) of Syzygium sp. tea leaves were commercially acquired in the cities of Juiz de Fora, Lavras, and Uberaba, in the state of Minas Gerais, Brazil. For all samples, at the time of purchase, an award was provided by the supplier with information such as botanical analysis, organoleptic, physicochemical, microbiological, and general identification tests. The tea leaves were immersed in boiling water at a ratio of 1 : 200 (gram/milliliter) for 10 minutes, simulating domestic use. The mixture was filtered through organza tissue, and the crude extract obtained was used in all trials.

2.2. Enzymatic Activity

Enzymes porcine pancreatic α-amylase type VIB (Sigma®) and porcine pancreatic trypsin (Merck®) were commercially obtained. The α-amylase activity was determined by the methodology proposed by Noelting and Bernfeld [14]. The product was read in a spectrophotometer at 540 nm. Each sample (A, B, C, D, and E) was evaluated at least three times in separate experiments. The enzymatic inhibition of α-amylase was expressed in percentage.

The trypsin activity was determined according to the methodology proposed by Erlanger et al. [15]. The absorbance of the product was read in a spectrophotometer at 410 nm. Enzymatic activity trials were performed in the presence of a simulated gastric fluid in order to simulate in vitro the digestion process in the stomach. To this end, the extracts were incubated with the simulated gastric fluid prepared according to The United States Pharmacopeia (USP) [16]. The activity trials were then performed.

The enzyme inhibition was obtained by determining the slopes of the lines (absorbance vs. time) testing the activity control (without extract) and sample (with extract). The slope of the line is due to the rate of product formation per minute of reaction, and the presence of the inhibitor causes a decrease in this gradient, expressed in percentage terms. All analyses were performed in triplicate.

2.3. Enzymatic Kinetics of α-Amylase

The enzymatic kinetics of α-amylase inhibitors were evaluated using standard experiment conditions [17] described for α-amylase activity. The trials were performed with increasing concentrations of the substrate (10 to 100 μL starch) in the absence and presence of the samples (A, B, C, D, and E). The mode of inhibition was determined graphically from the Michaelis–Menten equation and subsequently, based on the Lineweaver–Burk plot, for determination of the affinity (Km) and inhibition (Ki).

2.4. Quantification of Tannin Content, Flavonols, and Flavones and Qualitative Test for Alkaloids and Antioxidant Activity

The total polyphenols were determined according to the methodology of Folin–Ciocalteu modified by Singleton and Rossi [18]. The product was read in a spectrophotometer at 765 nm. Each sample (A, B, C, D, and E) was evaluated at least three times in separate experiments. Total phenol content was expressed as milligram of gallic acid equivalent per liter of infusion (mg GAE/L).

The tannin content was determined using the method described by Seigler et al. [19]. Absorbance was recorded using a spectrophotometer at 725 nm, and the total tannin content was determined from a calibration curve constructed with tannic acid as standard. The results were expressed as milligram of tannic acid equivalent (TAE) per milliliter of infusion (mg TAE/mL infusion).

The flavonoid content was determined by the colorimetric method of aluminum chloride as described by Chang et al. [20]. The flavonols and flavones content was determined by a calibration curve with different concentrations of quercetin. The results were expressed as milligram of quercetin equivalent (QE) per milliliter of infusion (mg QE/mL infusion).

The identification of alkaloids in the extracts was performed according to the method described by Costa [21]. About 50 μL of the samples were mixed with 50 μL of Mayer, Dragendorff, Wagner, and Bertrand reagents to verify the positivity of the reaction (precipitate formation). Atropine was used as positive control.

The antioxidant activity (AA) was evaluated by the ability of the samples to donate hydrogen to the DPPH, modifying the color of the solution according to the method described by Yamaguchi et al. [22]. Each sample (A, B, C, D, and E) was evaluated at least three times in separate experiments. The antioxidant activity of the infusion was obtained according to the formula:

2.5. Maldi-Tof Spectroscopy

The sample were subjected to Maldi-Tof spectroscopy diluted with 1 M solution of alpha-cyano-4-hydroxycinnamic acid (CHCA) in acetonitrile at a ratio of 1 : 1 (v/v).

2.6. Molecular Docking Simulations

Molecular docking simulations were performed using AutoDock 4.2 [23], and simulation analysis and visualization were performed using AutoDockTools 1.5.6 [24]. The crystalline structure was obtained from the Protein Data Bank [25], whose PDB codes were for luteolin (4QYA) and alpha-amylase (1PPI). The docking protocol was employed based in the previous work of Rettondin et al. [26].

2.7. Statistical Analysis

The tests were performed in triplicate, the data were entered in an Excel worksheet, and the results were analyzed using the SISVAR software.

3. Results and Discussions

3.1. Inhibition of α-Amylase

The enzymatic inhibitions of α-amylase and trypsin, before and after exposure to a simulated gastric fluid, by the Syzygium sp. samples are shown in Table 1.


Sampleα-AmylaseTrypsin
Mean1 ± SDMean1 ± SD

A13.23 ± 3.29a113.47 ± 12.62a1
30.86 ± 20.49a10.00 ± 0.00a1
B13.20 ± 1.86a16.88 ± 0.24a1
20.25 ± 25.57a10.00 ± 0.00a1
C0.00 ± 0.00a19.88 ± 3.67a1
35.79 ± 19.50a115.45 ± 11.54a1
D31.67 ± 10.93a111.22 ± 3.83a1
0.00 ± 0.00a111.88 ± 6.43a1
E13.19 ± 4.44a18.79 ± 1.52a1
0.00 ± 0.00a110.75 ± 8.05a1

1Average percentage obtained from three separate experiments ± standard deviation. a1, a2Statistical variation between the results of the sample according to Scott–Knott (). Superscript letters with same number represent results without a significant difference.

Considering the α-amylase activity, varied percentages of inhibition of the five samples (A, B, C, D, and E) were observed before (0% to 31.67%) and after simulated gastric fluid exposure (0% to 35.79%). It is observed that α-amylase in samples A, B, and C showed an increase in the percentage of enzymatic inhibition after exposure to the simulated gastric fluid. On the contrary, samples D and E reduced the α-amylase inhibition percentage after contact with gastric fluid.

Thus, considering the different behaviors regarding enzymatic inhibition, it is suggested that, although all the samples are marketed as “jambolão,” their phytochemicals content and biological activity may be different. It is emphasized here that the possible differences in phytochemical content and biological activity may be related to edaphoclimatic conditions, contaminations, and other factors.

Freitas et al. [27] demonstrated that infusions of Syzygium sp. leaves at different dilutions (1 : 20, 1 : 50, and 1 : 100) show high percentages of α-amylase enzyme inhibition before exposure to gastric fluid (above 90% in all dilutions). The authors suggested a possible relationship between amylase inhibition and the presence of phenolic compounds. Poongunran et al. [28], working with dried leaves of Syzygium cumini, found that extracts of methanol and water had high α-amylase inhibitory activity (98.3 ± 2.3 and 98.6 ± 1.6, respectively). The authors reported that the strong inhibition of the enzyme is due to the presence of oleanolic acid and ursolic acid, isolated from the leaves of Syzygium.

The extracts of Syzygium sp. at the 1 : 200 dilution showed lower enzymatic inhibition than those obtained in other studies, probably due to the higher dilution of the samples. It is suggested that the dilution is directly related to the possible hypoglycemic potential, considering the domestic use of leaf infusions of Syzygium sp.

After exposure of the extracts to a simulated gastric fluid, similar results were obtained by Freitas et al. [27], working with leaves of Syzygium sp., and by Pereira et al. [29], working with green and black teas. In both cases, the authors attributed the drop or disappearance of inhibition to the structural or conformational changes of the inhibitor caused by the acid medium. Such hypothesis suggests that although there is a hypoglycemic potential of Syzygium sp. tea, its passage through the gastric environment after ingestion would reduce the action that would occur later in the intestinal environment. However, biological trials are necessary to evaluate in vivo behavior and to validate such hypothesis.

3.2. Inhibition of Trypsin

In α-amylase inhibition, trypsin results showed a mean variation ranging from 6.88% to 13.47% inhibition before the fluid and from 0% to 15.45% after the simulated gastric fluid (Table 1).

Trypsin samples A and B had a decrease in inhibition percentage after gastric fluid, and sample C had an increase in inhibition. Sample D, however, maintained the percentage of inhibition before and after the fluid, and sample E had a slight increase after exposure to the simulated gastric fluid. As it was observed for α-amylase, the trypsin inhibition results also suggest that the phytochemicals content and biological activity may be different in the commercialized samples.

Pereira et al. [30], working with inhibition of digestive enzymes by extracts of Hoodia gordonii, did not detect trypsin inhibition. On the contrary, Marques et al. [31], who evaluated the enzymatic inhibition by hops pellets, reported a high inhibition of trypsin before and after exposure to gastric fluid with values of 67.48% and 89.01%, respectively.

The trypsin inhibitors present in plant extracts may lead to a decrease in protein digestibility, which may cause a reduction in the growth rate in animals and also a reduction in weight [31]. The passage of the Syzygium sp. extract through the gastrointestinal tract could cause structural changes and deformations in the inhibitors due to the acidic pH of the stomach, inactivating them [29, 31].

3.3. Antioxidant Capacity and Total Phenolic Compounds Content

The antioxidant capacity and the total phenolic compounds content in the Syzygium sp. samples are shown in Table 2.


SampleAntioxidant capacity (%)Total phenolic compounds (mg GAE/L infusion)
Mean1 ± SDMean1 ± SD

A51.49 ± 3.12a129.22 ± 6.45a1
B67.40 ± 8.23a124.55 ± 7.38a1
C76.97 ± 0.36a327.22 ± 1.26a1
D89.00 ± 2.84a441.22 ± 9.43a1
E67.24 ± 0.46a121.00 ± 6.44a1

1Average percentage obtained from three separate experiments ± standard deviation. a1, a2, a3, a4Statistical variation between the results of the sample according to Scott–Knott (). Superscript letters with same number represent results without significant difference.

The mean percentage of antioxidant activity varied from 51.49% (sample A) to 89.00% (sample D). The total phenolic compounds content ranged from 21.00 mg GAE/L infusion (sample E) to 41.22 mg GAE/L infusion (sample D).

By relating the percentage of inhibition of amylase with antioxidant capacity and total phenolic compounds, it can be observed that sample D showed the highest values of antioxidant capacity and total phenolics with the highest percentage of α-amylase inhibition before exposure to the gastric fluid. On the contrary, sample C, with the second largest antioxidant capacity and third in the total phenolic content, showed no inhibition against α-amylase, before exposure to the simulated gastric fluid. These findings reinforce the hypothesis of lack of standardization of the samples, which can, therefore, lead them to present different effects when it comes to helping in the treatment of diabetes and obesity.

Adefegha and Oboh [32] demonstrated that the soluble phenolic extract of Syzygium aromaticum possesses α-amylase and α-glucosidase inhibitory activity in a dose-dependent manner. For the antioxidant activity, the authors evaluated the reducing power of the DPPH radical, and their results revealed that scavenged DPPH radicals in a dose-dependent manner (104.17–416.67 µg/mL). However, judging by the IC50, there was no significant difference in the DPPH radical-scavenging ability of free soluble phenolic extract (212.53 µg/mL) and bound phenolic extract (256.14 µg/mL). Adefegha and Oboh [32] suggested that the antioxidant properties of phenolic compounds could be part of the possible mechanism that induces the antidiabetic effects of the plant.

Ruan et al. [33], when evaluating the antioxidant activity of “jambolão” leaves, showed that the total phenolic content in the methanolic extract of Syzygium cumini was 610.32 ± 9.03 mg/g. The methanolic extract of the leaves was fractionated in water for the analysis of the antioxidant potential. At the concentration of 15.63 μg/mL DPPH, 91.03% of DPPH remnant was obtained, while at the concentrations of 31.25 μg/mL, 62.4 μg/mL, and 125 μg/mL DPPH, the remaining percentages were, respectively, 86.02%, 75.72%, and 56.85%. The authors, Pereira et al. [29], suggested that the antioxidant activity of Syzygium cumini leaves may be related to the presence of phenolic compounds. A significant linear relationship between antioxidant potency, free radical-scavenging ability, and the content of phenolic compounds of leaf extracts supported this observation.

3.4. Quantification of Tannin Content, Flavonols, and Flavones and Qualitative Test for Alkaloids

The presence of bioactive compounds in leaves of “jambolão” is supposedly related to its beneficial effects for the organism. In this sense, the phytochemical screening of the samples was carried out. The samples had tannin content ranging from 0.0279 ± 0.011 to 0.0369 ± 0.002 mg TAE/mL infusion. The highest content of flavonols and flavones was found in sample D (0.0201 ± 0.0079 mg QE/mL infusion). Additionally, alkaloid was not detected in any of the analyzed samples, but only precipitate formed in the positive control. Although other authors have detected the presence of alkaloids in samples of the genus Syzygium, it is known that several factors may interfere in the phytochemical composition (part of the plant used, harvest season, seasonality, cultivation and climate, and type of the extractor) [3436] and explain the results obtained in the samples tested.

According to a study carried out by Faria et al. [37], the tannin content found in the functional extract (extract rich in anthocyanins extracted from the fruits of “jambolão”)—0.2 mg TAE/100 g sample—was lower in comparison with the fruit—3.9 mg TAE/100 g sample. High levels of tannins are undesirable in foods because of the astringent taste due to complexation with proteins and other effects that these compounds can cause.

Etxeberria et al. [38] report in their review article that 22 flavonoids were evaluated for their inhibitory activity against α-glycosidase. Among them, isoflavones and luteolin showed lower IC50. In addition, luteolin was more efficient than acarbose in inhibiting α-amylase. In contrast, in another study of this review, the authors concluded that the flavonoids tested did not have sufficient efficiency to delay or inhibit the release of glucose in the gastrointestinal tract [38].

3.5. Maldi-Tof Spectroscopy

Analyses were performed in Maldi-Tof spectroscopy to investigate the presence of phenolic compounds known to be α-amylase inhibitors. By analyzing Figures 1(a)1(e) regarding the Maldi-Tof spectrometry of the Syzygium sp. sheet extracts, it can be seen that there is a peak in the region of molar mass near luteolin (molar mass = 286.24 g/mol) in the five pure samples. Concerning the gastric fluid samples, the peak is not present in Sample A.

As demonstrated in some studies [39, 40], phenolic compounds present great inhibition of digestive enzymes, raising hypotheses about their potential use in the treatment of diabetes and obesity. However, most of these works are limited to enzyme activity trials, and the possible mechanisms of these inhibitions are not described. Among the phenolics, the flavonoid luteolin (Figure 2) stands out in which inhibitory potentials of α-glycosidase and α-amylase have been demonstrated [38, 39]. Luteolin has been described as an important α-amylase inhibitor present in seeds of Syzygium cumini [39]. However, its presence in leaves of Syzygium sp., and particularly in commercial tea, has not been reported yet.

In addition to luteolin, Karthic et al. [39] and Poongunran et al. [28] describe in their studies the presence of other α-amylase and α-glycosidase inhibitors in seeds and leaves of Syzygium cumini, respectively. They are betulinic acid, ursolic acid, and oleanolic acid, all with molecular weight of 456.7 g/mol. However, in the present study, no peaks were found in this region in any of the samples.

Although the presence of luteolin has been suggested (except for sample A with fluid), the fact that it is a complex matrix may be the responsible for the variation of the profile of enzymatic inhibition between the samples, either by inactivation or stimulation. This variation might be associated with the lack of standardization of samples.

3.6. Enzymatic Kinetics

Regarding the kinetic study, all samples showed uncompetitive inhibition against α-amylase as shown in Table 3.


SampleVmax with inhibitorKiInhibition

A0.0811.17Uncompetitive
B0.3232.78Uncompetitive
C0.0900.45Uncompetitive
D0.2962.86Uncompetitive
E0.3293.34Uncompetitive

The values of Vmax and Km obtained were 0.430 and 6.67, respectively, for all samples. In this type of inhibition, the inhibitor only binds to the enzyme-substrate (ES) complex. The free enzyme does not interact with the inhibitor; i.e., the mixed inhibitor binds only to the ES complex of the enzyme leading to an inactive complex, ESI. Inhibition is not reversed by the increase in substrate concentration. The result is the apparent modification (decrease) of Km and Vmax [41].

In a study by Ponnusamy et al. [42], the aqueous extracts of the Syzygium cumini seed exhibited concentration-dependent (competitive) inhibition. In contrast, Tong et al. [12] demonstrated that water-soluble tannins isolated from the Eugenia jambolana methanolic tea inhibited α-amylase in a noncompetitive manner.

3.7. Molecular Docking

Molecular docking was performed in order to theoretically assess the interactions between the pancreatic α-amylase and the luteolin compound. This approach predicts the conformation of a ligand within the active site of a receptor and the mode of binding with less energy between the ligand-receptor complex. Figure 3 shows the predicted lowest binding mode resulting from the docking simulations of α-amylase complexed with luteolin. In Figure 3, eight hydrophobic interactions and three hydrogen bonds between luteolin and the enzyme residues were identified. Regarding the hydrogen bonds, two of them (His201 and His299) appear in the X-ray crystal structure between α-amylase and the carbohydrate inhibitor, which is double the size of luteolin and has four histidines coordinating the protein-inhibitor hydrogen bond interactions [43]. The carboxylic oxygens of the catalytic residues Glu233 and Asp300 form hydrogen bonds in the X-ray complex; therefore, in the predicted α-amylase-luteolin complex, they are present as hydrophobic interactions. The third residue of the catalytic triad Asp197 is located on the opposite side of the inhibitor binding cleft (according to the crystallographic structure) and does not have a close interaction with luteolin. However, hydrophobic stacking of aromatic residues with the inhibitor surface occurs in a similar manner in both structures.

AutoDock free-energy scoring function was used to estimate the complex binding energy (ΔG). The best-ranked α-amylase-luteolin complex from Figure 3 resulted in a stable structure (ΔG=8.2 kcal·mol−1), when compared to the binding free energy calculated for the X-ray complex α-amylase-acarbose (ΔG=13.7 kcal·mol−1). Although not always the most stable system leads to active conformation, the best-ranked conformation of α-amylase-luteolin complex resulted in a similar binding free energy as the native complex α-amylase-acarbose when performing redocking experiments.

The use of the molecular docking tools in theoretical studies has become increasingly attractive and relevant to the understanding of protein-ligand interactions in order to support experimental results and predict binding modes. In this study, molecular docking simulations were performed to investigate the luteolin mechanism of interaction with α-amylase as a comparison with the carbohydrate enzyme inhibitor present in the experimental structure. Competitive inhibition could be expected as molecular docking analysis predicted that both acarbose and luteolin bind at the same α-amylase active site with similar binding free energy. Therefore, it is hypothesized that there are other inhibitory compounds present in the aqueous extracts of Syzygium sp., as shown by the enzymatic kinetics assay. Thus, it is possible that, in addition to luteolin, other inhibitory compounds are present, or that, corroborating the other findings, and the complex matrix of each extract is also responsible for the variation of the inhibitory profile.

4. Conclusion

The aqueous extracts of Syzygium sp., obtained by 1 : 200 infusion, present low percentages of inhibition of the digestive enzymes, suggesting a decrease in the potential hypoglycemic effect at this dilution. Thus, considering the different profiles of enzymatic inhibition, it is suggested that the phytochemical content and biological activity of samples may be distinct, in spite of their commercialization as “jambolão.” Although the antioxidant activity of the tea was significant, the contents of phenolic compounds, flavonoids, flavones, alkaloids, and tannins were not expressive at the 1 : 200 dilution. The results regarding the Maldi-Tof spectroscopy revealed a peak around 284 in the mass region (m/z), suggesting the presence of luteolin. It was proposed that luteolin binds with α-amylase enzyme in a similar manner as the carbohydrate inhibitor present in the X-ray structure. Even though both inhibitors bind with the catalytic active site, enzymatic kinetics trials demonstrated uncompetitive inhibition, indicating that there are other enzymatic inhibitors present. Therefore, the complex matrix of the Syzygium sp. extract may also be responsible for the variation of the inhibitory profile of the samples.

Considering that the phytochemical content and biological activity may be distinct among samples, the use of such extract by the population to aid in the treatment of diabetes and obesity is still not recommended. Additional in vivo studies should be conducted to elucidate the efficacy and safety of the use of extracts of Syzygium sp.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors thank Dra. Angelica N. Lima for the assistance with the docking simulations. This research was supported by funding awards from Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES). The authors thank FAPEMIG for the financial support in the form of a master’s degree scholarship. The authors also thank the facilities GridUNESP and CENAPAD-SP for the computational resources. This work is part of a research project collaboration among members of the Rede Mineira de Química (RQ-MG) supported by FAPEMIG (project nos REDE-113/10 and CEX-RED-00010-14). This manuscript is based on Tuanny Cavatão de Freitas’s master’s thesis entitled “Syzygium sp: compostos bioativos e ação sobre as enzimas digestivas” [44] from Programa Interdisciplinar em Biociências Aplicadas, Universidade Federal do Triângulo Mineiro.

References

  1. R. S. Aguiar and R. Manini, “The physiology of obesity: genetic, environmental bases and its relationship with diabetes,” With Science, vol. 145, 2013. View at: Google Scholar
  2. M. F. M. de Araújo, T. M. de Araújo, P. d. J. d. S. Alves, V. S. Veras, M. L. Zanetti, and M. M. C. Damasceno, “Uso de medicamentos, glicemia capilar e índice de massa corpórea em pacientes com diabetes mellitus,” Revista Brasileira de Enfermagem, vol. 66, no. 5, pp. 709–714, 2013. View at: Publisher Site | Google Scholar
  3. P. R. D. Perera, S. Ekanayake, and K. K. D. S. Ranaweera, “Antidiabetic compounds in Syzygium cumini decoction and ready to serve herbal drink,” Evidence-Based Complementary and Alternative Medicine, vol. 2017, Article ID 1083589, 5 pages, 2017. View at: Publisher Site | Google Scholar
  4. International Diabetes Federation (IDF), 2017, http://www.idf.org.
  5. R. Sundaram, R. Naresh, R. Ranadevan, P. Shanthi, and P. Sachdanandam, “Effect of iridoid glucoside on streptozotocin induced diabetic rats and its role in regulating carbohydrate metabolic enzymes,” European Journal of Pharmacology, vol. 674, no. 2-3, pp. 460–467, 2012. View at: Publisher Site | Google Scholar
  6. K. M. M. John, M. Ayyanar, S. Jeeva, M. Suresh, G. Enkhtaivan, and D. H. Kim, “Metabolic variations, antioxidant potential, and antiviral activity of different extracts of Eugenia singampattiana (an endangered medicinal plant used by kani tribals, Tamil nadu, India) leaf,” BioMed Research International, vol. 2014, Article ID 726145, 11 pages, 2014. View at: Publisher Site | Google Scholar
  7. T. Widyawati, N. Yusoff, M. Asmawi, and M. Ahmad, “Antihyperglycemic effect of methanol extract of Syzygium polyanthum (wight.) leaf in streptozotocin-induced diabetic rats,” Nutrients, vol. 7, no. 9, pp. 7764–7780, 2015. View at: Publisher Site | Google Scholar
  8. T. Freitas, L. Pereira, and C. Pereira, “Syzygium sp. (Myrtaceae): promising for diabetes treating?” European Journal of Medicinal Plants, vol. 7, no. 4, pp. 167–176, 2015. View at: Publisher Site | Google Scholar
  9. L. Chanudom and J. Tangpong, “Anti-inflammation property of Syzygium cumini (L.) skeels on indomethacin-induced acute gastric ulceration,” Gastroenterology Research and Practice, vol. 2015, Article ID 343642, 12 pages, 2015. View at: Publisher Site | Google Scholar
  10. S. Tucci, E. J. Boyland, and J. C. Halford, “The role of lipid and carbohydrate digestive enzyme inhibitors in the management of obesity: a review of current and emerging therapeutic agents,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 2010, no. 3, pp. 125–143, 2010. View at: Publisher Site | Google Scholar
  11. T. Manaharan, D. Appleton, H. M. Cheng, and U. D. Palanisamy, “Flavonoids isolated from Syzygium aqueum leaf extract as potential antihyperglycaemic agentes,” Food Chemistry, vol. 132, no. 4, pp. 1802–1807, 2011. View at: Publisher Site | Google Scholar
  12. W. Y. Tong, H. Wang, V. Y. Waisundara, and D. Huang, “Inhibiting enzymatic starch digestion by hydrolyzable tannins isolated from Eugenia jambolana,” LWT-Food Science and Technology, vol. 59, no. 1, pp. 389–395, 2014. View at: Publisher Site | Google Scholar
  13. A. A. Simão, A. D. Corrêa, and P. M. B. Chagas, “Inhibition of digestive enzymes by medicinal plant aqueous extracts used to aid the treatment of obesity,” Medicinal Plants Research, vol. 6, no. 47, pp. 5826–5830, 2012, https://academicjournals.org/journal/JMPR/article-abstract/D7D39A023417. View at: Google Scholar
  14. G. Noelting and P. Bernfeld, “Sur les enzymes amylolytiqucs III. La β-amylase: dosage d’activité et contrôle de l’absence d’α-amylase,” Helvetica Chimica Acta, vol. 31, no. 1, pp. 286–290, 1948. View at: Publisher Site | Google Scholar
  15. B. F. Erlanger, N. Kokowsky, and W. Cohen, “The preparation and properties of two new chromogenic substrates of trypsin,” Archives of Biochemistry and Biophysics, vol. 95, no. 2, pp. 271–278, 1961. View at: Publisher Site | Google Scholar
  16. The United States Pharmacopeia (USP), The National Formulary NF 18, Pharmacopeial Convention Ing., Rockville, MD, USA, 1995.
  17. C. Yung-Chi and W. H. Prusoff, “Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction,” Biochemical Pharmacology, vol. 22, no. 23, pp. 3099–3108, 1973. View at: Publisher Site | Google Scholar
  18. V. L. Singleton and J. A. Rossi, “Colorimetry of total phenolics with phosphomolybdic phosphotungstic acid reactants,” American Journal of Enology and Viticulture, vol. 16, no. 3, pp. 144–158, 1965. View at: Google Scholar
  19. D. S. Seigler, S. Seilheimer, J. Keesy, and H. F. Huang, “Tannins from four commonAcacia species of Texas and Northeastern Mexico,” Economic Botany, vol. 40, no. 2, pp. 220–232, 1986. View at: Publisher Site | Google Scholar
  20. Q. C. Chang, M. H. Yang, H. M. Wen, and J. C. Chern, “Estimation of total flavonoid content in propolis by two complementary colorimetric methods,” Journal Of Food And Drug Analysis, vol. 10, pp. 178–182, 2002. View at: Google Scholar
  21. A. F. Costa, Pharmacognosy, Calouste Gulbenkian Foundation, Lisbon, Portugal, 2002.
  22. T. Yamaguchi, H. Takamura, T. Matoba, and J. Terao, “HPLC method for evaluation of the free radical-scavenging activity of foods by using 1,1-Diphenyl-2-picrylhydrazyl,” Bioscience, Biotechnology, and Biochemistry, vol. 62, no. 6, pp. 1201–1204, 2014. View at: Publisher Site | Google Scholar
  23. D. S. Goodsell, G. M. Morris, and A. J. Olson, “Automated docking of flexible ligands: applications of autodock,” Journal of Molecular Recognition, vol. 9, no. 1, pp. 1–5, 1996. View at: Publisher Site | Google Scholar
  24. M. F. Sanner, “Python: a programming language for software integration and development,” Journal of Molecular Graphics and Modeling, vol. 17, pp. 57–61, 1999. View at: Google Scholar
  25. PubChem–Open Chemistry Data Base, Luteolin, November 2018, https://pubchem.ncbi.nlm.nih.gov/compound/luteolin#section=Top.
  26. A. R. Rettondin, Z. A. Carneiro, A. C. R. Gonçalves et al., “Gold (III) complexes with ONS-Tridentate thiosemicarbazones: toward selective trypanocidal drugs,” European Journal of Medicinal Chemistry, vol. 120, pp. 217–226, 2016. View at: Publisher Site | Google Scholar
  27. T. C. Freitas, C. A. Pereira, and L. L. S. Pereira, “Syzygium sp. (Myrtaceae) extracts: inhibition of alpha amylase,” European Journal of Medicinal Plants, vol. 4, no. 1, pp. 116–125, 2014. View at: Publisher Site | Google Scholar
  28. J. Poongunran, H. K. I. Perera, L. Jayasinghe et al., “Bioassay-guided fractionation and identification of α-amylase inhibitors from Syzygium cumini leaves,” Pharmaceutical Biology, vol. 55, no. 1, pp. 206–211, 2016. View at: Publisher Site | Google Scholar
  29. L. L. S. Pereira, S. P. Souza, M. C. Silva et al., “Glucosidase activity in the presence of green tea and black tea,” Revista Brasileira de Plantas Medicinais, vol. 12, no. 4, pp. 516–518, 2010. View at: Publisher Site | Google Scholar
  30. L. L. S. Pereira, C. D. dos Santos, L. C. Sátiro, S. Marcussi, C. A. Pereira, and S. P. de Souza, “Inhibitory action and stability of the extract of white bean flour on digestive enzymes in the presence of simulated gastric fluid,” Revista brasileira de farmácia, vol. 92, pp. 367–372, 2011. View at: Google Scholar
  31. T. R. Marques, L. L. S. Pereira, A. A. Simão et al., “Inhibition of digestive enzymes by hop pellets (Humuluslupulus L.),” Brazilian Journal of Biosciences, vol. 12, pp. 183–187, 2014. View at: Google Scholar
  32. S. A. Adefegha and G. Oboh, “In vitro inhibition of polyphenol-rich extracts from Syzygium aromaticum (L.) Merr. & Perry (Clove) buds against carbohydrate hydrolyzing enzymes linked to type 2 diabetes and Fe2+-induced lipid peroxidation in rat pancreas,” Asian Pacific Journal of Tropical Biomedicine, vol. 2, no. 10, pp. 774–781, 2012. View at: Publisher Site | Google Scholar
  33. Z. P. Ruan, L. L. Zhang, and Y. M. Lin, “Evaluation of the antioxidant activity of Syzygium cumini leaves,” Molecules, vol. 13, no. 10, pp. 2545–2556, 2008. View at: Publisher Site | Google Scholar
  34. A. Maroyi, “Syzygium cordatum hochst. Ex krauss: an overview of its ethnobotany, phytochemistry and pharmacological properties,” Molecules, vol. 23, no. 5, p. 1084, 2018. View at: Publisher Site | Google Scholar
  35. A. A. Shad, S. Ahmad, R. Ullah et al., “Phytochemical and biological activities of four wild medicinal plants,” Scientific World Journal, vol. 2014, Article ID 857363, 7 pages, 2014. View at: Publisher Site | Google Scholar
  36. A. Pandey and S. Tripathi, “Concept of standardization, extraction and pre phytochemical screening strategies for herbal drug,” Journal of Pharmacognosy and Phytochemistry, vol. 2, pp. 115–119, 2014. View at: Google Scholar
  37. A. F. Faria, M. C. Marques, and A. Z. Mercadante, “Identification of bioactive compounds from jambolãn (Syzygium cumini) and antioxidant capacity evaluation in different pH conditions,” Food Chemistry, vol. 126, no. 4, pp. 1571–1578, 2011. View at: Publisher Site | Google Scholar
  38. U. Etxeberria, A. L. de la Garza, J. Campión, J. A. Martínez, and F. I. Milagro, “Antidiabetic effects of natural plant extracts via inhibition of carbohydrate hydrolysis enzymes with emphasis on pancreatic alpha amylase,” Expert Opinion on Therapeutic Targets, vol. 16, no. 3, pp. 269–297, 2012. View at: Publisher Site | Google Scholar
  39. K. Karthic, K. S. Kirthiram, S. Sadavisam, and B. Thayumanavan, “Identification of α amylase inhibitors from Syzygium cumini Linn seeds,” Indian Journal of Experimental Biology, vol. 46, no. 9, pp. 677–680, 2008. View at: Google Scholar
  40. J. Yan, G. Zhang, J. Pan, and Y. Wang, “Alfa-Glucosidase inhibition by luteolin: kinetics, interaction and molecular docking,” International Journal of Biological Macromolecules, vol. 64, pp. 213–223, 2014. View at: Publisher Site | Google Scholar
  41. D. L. Nelson and M. M. Cox, Principles of Biochemistry–Lehninger, W. H. Freeman and Company, New York, NY, USA, 6th edition, 2013.
  42. S. Ponnusamy, R. Ravindran, S. Zinjarde, S. Bhargava, and A. R. Kumar, “Evaluation of traditional Indian antidiabetic medicinal plants for human pancreatic amylase inhibitory effect in vitro,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 515647, 10 pages, 2011. View at: Publisher Site | Google Scholar
  43. M. Qian, R. Haser, G. Buisson, E. Duee, and F. Payan, “The active center of a mammalian alpha-amylase. Structure of the complex of a pancreatic alpha-amylase with a carbohydrate inhibitor refined to 2.2-A resolution,” Biochemistry, vol. 33, no. 20, pp. 6284–6294, 1994. View at: Publisher Site | Google Scholar
  44. T. Freitas, “Syzygium sp.: compostos bioativos e ação sobre as enzimas digestivas,” Master’s thesis, Universidade Federal do Triângulo Mineiro, Uberaba, Brazil, 2017. View at: Google Scholar

Copyright © 2019 Tuanny Cavatão de Freitas et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1121 Views | 462 Downloads | 0 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.